Nevertheless, analysis of the levels of αvβ3 and αvβ5 integrins, the targets of cilengitide, in tumor samples from glioblastoma patients enrolled in the phase II CORE clinical trial revealed that higher αvβ3 levels in tumor tissue were associated with improved PFS and OS in patients lacking MGMT promoter methylation treated with cilengitide. This evidence concerns the gene MGMT and glioblastoma.